Results 201 to 210 of about 4,615,200 (301)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Reducing the solicitor's burden [PDF]

, 2001
Andrews, Georgina
core  

Beyond Anticholinergic Burden: An Integral Theory Perspective on Overactive Bladder - A Commentary on "A Retrospective Database Analysis of Anticholinergic Burden Among Older Patients With and Without Overactive Bladder in South Korea". [PDF]

Int Neurourol J
Tayarer A.
europepmc   +1 more source

Shifting the Burden [PDF]

Science, 1957
openaire   +2 more sources

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Role of Sense of Coherence in Mediating the Relationship Between End-of-Life Caregiving Burden and Bereavement Depressive-Symptom Trajectory. [PDF]

J Nurs Res
Wen FH, Chou WC, Hou MM, Su PJ, Shen WC, Chen JS, Chang WC, Tang ST.   +7 more
europepmc   +1 more source

The caries burden [PDF]

British Dental Journal, 2013
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Global, regional and national burden of polycystic ovary syndrome: historical trends from 1990 to 2021 and projections to 2035. [PDF]

Front Endocrinol (Lausanne)
Li H, Jing Z, Li R, Shen Z, Bai T, Song Q.   +5 more
europepmc   +1 more source